期刊
LUNG CANCER
卷 41, 期 -, 页码 S29-S42出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/S0169-5002(03)00137-5
关键词
lung cancer; epidermal growth factor; targeted therapy; immunohistochemistry; fluorescence in situ hybridization
资金
- NCI NIH HHS [3P50 CA 58187] Funding Source: Medline
The Erb-B family of receptors plays an important role in lung carcinogenesis and tumor development, and EGFR and HER2 are highly expressed in bronchial preneoplasia. In invasive tumors, EGFR are expressed in 50-90%, and mostly in squamous cell carcinomas, but also in adenocarcinomas and large cell carcinomas, while HER2 is less frequently expressed (20-30%) and mostly expressed in adenocarcinomas. Bronchioloalveolar cell carcinomas may present a distinct EGFR profile compared to the other NSCLCs and evidence and consequences are discussed. The genetic mechanisms responsible for overexpression of EGFR and HER2 proteins might be numerous, including gene dosage (overrepresentation or amplification) as well as translational and post-translational mechanisms. However, for EGFR and HER2 there is a positive correlation between gene copy numbers and level of protein expression demonstrated by fluorescence in situ hybridization analysis and immunochemistry. Gene amplification for EGFR and HER2 is demonstrated in only 5-10% of the tumors. The treatment status and therapeutic [imitation with trastuzumab (Herceptin) in lung cancer compared to breast cancer is discussed. (C) 2003 Elsevier Science Ireland Ltd and American Society of Clinical Oncology. Published by Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据